Raising awareness of neuroendocrine cancers around the world

NET Cancer Day

November 10


May 14 2011

FDA Approves Everolimus as First New Treatment in Nearly 3 Decades for Advanced Pancreatic NET Patients

The US Food and Drug Administration (FDA) has approved Afinitor (everolimus) tablets for the treatment of progressive pancreatic neuroendocrine tumors in patients with unresectable, locally advanced or metastatic disease.  This marks the first approval of a treatment for pNET patients in the United States in almost 30 years. According to Novartis, which manufactures the drug, approximately 60% of patients with pNET exhibit advanced disease at the time of diagnosis.